IN002.5.1
/ Shenzhen Shenxin Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
May 03, 2024
A study to evaluate an mRNA COVID-19 vaccine (IN002.5.1) in comparison with an approved mRNA COVID-19 vaccine
(ANZCTR)
- P1 | N=60 | Completed | Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd. | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease
November 03, 2023
A study to evaluate an mRNA COVID-19 vaccine (IN002.5.1) in comparison with an approved mRNA COVID-19 vaccine
(ANZCTR)
- P1 | N=60 | Active, not recruiting | Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Novel Coronavirus Disease
September 01, 2023
A study to evaluate an mRNA COVID-19 vaccine (IN002.5.1) in comparison with an approved mRNA COVID-19 vaccine
(ANZCTR)
- P1 | N=60 | Recruiting | Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd. | Initiation date: Apr 2000 ➔ Apr 2023
Trial initiation date • Infectious Disease • Novel Coronavirus Disease
1 to 3
Of
3
Go to page
1